Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 449,295 shares of the company’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $14.33, for a total value of $6,438,397.35. Following the completion of the sale, the chief executive officer now directly owns 380,723 shares in the company, valued at $5,455,760.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Amicus Therapeutics, Inc. (FOLD) traded up 2.60% during mid-day trading on Friday, reaching $13.80. The company had a trading volume of 274,283 shares. The company’s market capitalization is $2.27 billion. The stock has a 50 day moving average of $14.35 and a 200-day moving average of $11.26. Amicus Therapeutics, Inc. has a 52 week low of $4.41 and a 52 week high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The company had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. During the same period in the previous year, the company earned ($0.40) EPS. On average, analysts expect that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/10/27/amicus-therapeutics-inc-fold-ceo-john-f-crowley-sells-449295-shares-of-stock.html.
Several equities research analysts recently commented on the company. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. BidaskClub downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Chardan Capital reissued a “buy” rating and issued a $16.50 target price (down previously from $17.50) on shares of Amicus Therapeutics in a report on Wednesday, September 13th. Finally, Robert W. Baird increased their target price on Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, July 12th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $17.81.
A number of large investors have recently bought and sold shares of FOLD. Janus Henderson Group PLC purchased a new position in Amicus Therapeutics in the 2nd quarter valued at about $70,762,000. Wellington Management Group LLP boosted its position in Amicus Therapeutics by 358.4% in the 1st quarter. Wellington Management Group LLP now owns 5,341,132 shares of the biopharmaceutical company’s stock valued at $38,083,000 after buying an additional 4,175,995 shares during the last quarter. Morgan Stanley boosted its position in Amicus Therapeutics by 99.4% in the 1st quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock valued at $43,696,000 after buying an additional 3,055,039 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Amicus Therapeutics in the 1st quarter valued at about $21,394,000. Finally, Farallon Capital Management LLC purchased a new position in Amicus Therapeutics in the 2nd quarter valued at about $30,210,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.